In addition, amivantamab is currently being tested in combination with platinum/pemetrexed as first-line therapy for EGFR Ex20+ NSCLC in the phase 3 PAPILLON trial (NCT4538664), in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib as first-line therapy for NSCLC with EGFR Ex19 deletions or p.L858R mutations in the phase 3 MARIPOSA study (NCT04487080) [86], and for subcutaneous administration (NCT04606381). This evidence concerns the gene EGFR and non-small cell lung carcinoma.